Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.

Details

• Lead Sponsor: Devalingam Mahalingam
• Collaborator: GenSpera, Inc.

Criteria

Inclusion Criteria:

• History of hepatocellular carcinoma

• Participation in prior research study where G-202 was administered

• Tolerance of G-202 treatment

• Demonstration of stable disease

Exclusion Criteria:

• Disease progression

• Occurrence of unacceptable toxicity